摘要
目的:观察厄贝沙坦/氢氯噻嗪片(含厄贝沙坦150 mg,氢氯噻嗪12.5 mg)与硝苯地平控释片(含硝苯地平30 mg)联合治疗高血压的临床疗效。方法:选择高血压患者78例,随机分为A组(口服厄贝沙坦/氢氯噻嗪片150 mg,每日1次)、B组(口服硝苯地平控释片30 mg,每日1次)、C组(晨服厄贝沙坦/氢氯噻嗪片150 mg,睡前服用硝苯地平控释片30 mg,每日1次),疗程均为12周。结果:3组患者血压均有下降(P<0.01),总有效率A组为61.9%,B组为64.0%,C组为93.8%,差异有统计学意义(P<0.05)。结论:厄贝沙坦/氢氯噻嗪联合硝苯地平控释片治疗高血压比单用厄贝沙坦/氢氯噻嗪片或硝苯地平控释片更有效、安全,值得推广。
Objective：To observe the efficacy of irbesartan/hydrochlorothiazide tablets（IHT） and nifedipine controlled-release tablets（NCRT） in moderate to severe essential hypertension.Methods：Patients were randomly divided into A group（IHT 150 mg,per day,n=21）,B group（NCRT 30 mg per day,n=25）,C group（150 mg per morning,NCRT 30 mg per night,n=32）,three groups were all treated for 12 weeks.Results：Blood pressure of three groups all greatly decreased（P0.01）,the total effective rate in IHT groups was 61.9%;the total effective rate in NCRT groups was 64.0% the total effective rate in IHT ＋NCRT groups was 93.8%.Conclusions：IHT plus NCRT are more efficiency than IHT or NCRT group in the treatment of moderate to severe hypertension.So it deserve to popularize fore more efficiency and more security.
出处
《蚌埠医学院学报》
CAS
2011年第7期733-735,共3页
Journal of Bengbu Medical College
